Cambridge Cognition Holdings PLC represents a commitment to scientific excellence and innovation in cognitive research. With a focus on developing cutting-edge technology and software solutions, the company aims to transform the understanding and treatment of brain-related disorders. Cambridge Cognition places great emphasis on collaboration and partnerships with renowned academic institutions and pharmaceutical companies, allowing the company to remain at the forefront of cognitive science. With a dedication to improving patient outcomes, Cambridge Cognition strives to provide accurate and reliable assessments for clinical trials and patient care. By continuously pushing the boundaries of cognitive assessment, this company is leading the way in advancing neuroscience research.

Cambridge Cognition Holdings PLC is primarily present in the United Kingdom.

Cambridge Cognition Holdings PLC, a leading cognitive neuroscience company, has achieved significant milestones in its journey. The company has successfully developed and launched innovative digital health technologies and cognitive assessment solutions. It has collaborated with renowned research institutions and pharmaceutical companies, forging strong partnerships to advance scientific knowledge and drive clinical research. Cambridge Cognition Holdings PLC has also expanded its global reach, effectively penetrating new markets and establishing a solid presence across the globe. Through continuous innovation and dedication, the company has positioned itself as a trusted leader in the field, empowering researchers and clinicians to make informed decisions for better patient outcomes.

Cambridge Cognition Holdings PLC, a leading neuroscience technology company, has a rich history and background. Founded in 1999, the company focuses on developing cutting-edge digital health solutions. It began as a spin-out from the University of Cambridge, leveraging the world-class research and expertise of the university. Cambridge Cognition Holdings PLC has since established itself as a global leader in cognitive assessment and monitoring. Its innovative software tools and digital health technologies, backed by extensive research, enable the assessment of cognitive health and the early detection of neurological disorders. With a strong emphasis on scientific rigor and rigorous standards, Cambridge Cognition Holdings PLC continues to revolutionize cognitive healthcare.

Cambridge Cognition Holdings PLC faces competition from several key players in the market. Some of its main competitors include Cogstate Ltd, which offers cognitive assessment tools and services; ProPhase Labs Inc, known for their innovative cognitive health products; and Brain Resource Company Pty Ltd, a company that specializes in online brain health assessments and training. These competitors strive to offer similar services and solutions, creating a competitive landscape for Cambridge Cognition Holdings PLC.

Cambridge Cognition Holdings PLC is primarily active in the healthcare and pharmaceutical industries.

The business model of Cambridge Cognition Holdings PLC is focused on providing digital solutions in cognitive health, clinical trials, and neuroscience research. The company offers software tools and services that enable the assessment of cognitive function and mental health. Cambridge Cognition's technology is used by pharmaceutical companies, research institutions, and healthcare providers to improve the understanding and treatment of neurological and psychiatric disorders. With their innovative solutions and expertise in cognition, the company aims to help customers in accelerating drug development, advancing scientific research, and ultimately improving patient outcomes. Cambridge Cognition Holdings PLC is committed to delivering cutting-edge solutions in the field of cognitive health.

Το Cambridge Cognition Holdings P/E είναι -24,90.

Το KUV της εταιρείας Cambridge Cognition Holdings είναι 1,08.

Το AlleAktien Qualitätsscore για το Cambridge Cognition Holdings είναι 4/10.

Ο κύκλος εργασιών του αναμενόμενη Cambridge Cognition Holdings είναι 14,37 Εκ. GBP.

Το αναμενόμενη Cambridge Cognition Holdings κέρδος είναι -625.251,10 GBP.

Cambridge Cognition Holdings PLC is a leading company in the field of digital cognitive health research. The company's business model is based on the development and provision of software products to support clinical studies and research projects in the field of cognitive health. The company offers various digital tools that help measure and improve patients' cognitive health. The focus is on researching diseases such as Alzheimer's, schizophrenia, depression, and anxiety disorders. The tools include mobile applications, web applications, and software solutions that can run on tablets and other digital devices. Cambridge Cognition Holdings PLC distributes its tools and services to research institutes as well as companies in the pharmaceutical and biotech industries. The company works closely with its customers to develop and offer customized solutions. The latest scientific knowledge is used, and the needs and requirements of customers are taken into account when developing new products. Another important aspect of Cambridge Cognition Holdings PLC's business model is the acquisition of research projects. The company uses its own products and expertise to conduct clinical studies in the field of cognitive health. The data from these studies can then be used by the company's customers to develop new drugs and therapies. A central aspect of Cambridge Cognition Holdings PLC's business model is innovation. The company is constantly striving to further develop its products and services and offer new solutions in the field of digital cognitive health research. To this end, the company continuously invests in research and development and works closely with leading scientists in this field. Cambridge Cognition Holdings PLC aims to play a leading role in digital cognitive health research. The company relies on open and transparent collaboration with its customers and partners. By pooling resources and expertise, innovative solutions in the field of cognitive health are to be developed, which provide real added value for patients and society as a whole. Overall, Cambridge Cognition Holdings PLC's business model is focused on continuous growth and success. By developing and improving tools and services in the field of digital cognitive health research, the company aims to accelerate research and improve disease treatment.

Η Cambridge Cognition Holdings καταβάλλει μια διανομή της τάξεως των 0 GBP διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Cambridge Cognition Holdings αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Cambridge Cognition Holdings είναι GB00B8DV9647.

Το WKN της Cambridge Cognition Holdings είναι A1T9LW.

Ο τίκερ της Cambridge Cognition Holdings είναι COG.L.

Κατά τους τελευταίους 12 μήνες η Cambridge Cognition Holdings κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Cambridge Cognition Holdings προβλέπεται να πληρώσει μέρισμα 0 GBP.

Η απόδοση μερίσματος της Cambridge Cognition Holdings ανέρχεται σήμερα στο .

Cambridge Cognition Holdings πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Cambridge Cognition Holdings πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 GBP. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Cambridge Cognition Holdings ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Cambridge Cognition Holdings από την 31/8/2024 με τιμή 0 GBP, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 31/8/2024.

Η τελευταία μερίσματος έγινε στις 31/8/2024.

Το έτος 2023, η Cambridge Cognition Holdings διένειμε 0 GBP ως μερίσματα.

Τα μερίσματα του Cambridge Cognition Holdings καταβάλλονται σε GBP.